Transcatheter Aortic Valve Implantation (TAVI) Market by Procedure (Transfemoral Implantation, Transapical Implantation, and Transaortic Implantation) - Global Opportunity Analysis and Industry Forecast, 2018-2025
The transcatheter aortic valve implantation (TAVI) market revenue was valued at $2,761 million in 2017 and is expected to reach $8,138 million by 2025, growing at a CAGR of 13.8% from 2018 to 2025. The volume market was valued at 107,011 units in 2017 and is expected to reach 337,778 units by 2025, growing at a CAGR of 14.8% from 2018 to 2025.
Transcatheter aortic valve implantation (TAVI), also called as transcatheter aortic valve replacement (TAVR), is a minimally invasive surgical procedure, which is performed to treat high-risk patients suffering from aortic stenosis. These high-risk patients refer to the patient population who cannot undergo surgical aortic valve replacement (SAVR) procedure. Older population (above 75 years of age) falls under the high-risk category, as the open-heart procedure is too risky for them. TAVR involves implantation of transcatheter aortic valves to regenerate the blood circulation ability of the aortic valve. The need of transcatheter aortic valve implantation is on the rise due to the increase in prevalence of aortic stenosis.
TAVI experiences market growth due to rise in geriatric population. Furthermore, advancements in the transcatheter aortic valves and increase in adoption rate of TAVI devices drive the market. However, stringent government regulations for approval of transcatheter aortic valves, which are class III medical devices and high cost associated with TAVI hamper the market growth. Conversely, use of TAVI systems for new indications, rise in healthcare expenditure in emerging economies, and increase in the interest of key players in the TAVI market are projected to provide several growth opportunities for the market throughout the forecast period.
The report segments the TAVI market based on procedure and region. According to procedure, it is classified into transfemoral implantation, transapical implantation, and transaortic implantation. Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, Switzerland, UK, and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of Asia-Pacific), and LAMEA (Brazil, Israel, South Africa, Saudi Arabia, and Rest of LAMEA).
KEY BENEFITS
By Procedure
Transcatheter aortic valve implantation (TAVI), also called as transcatheter aortic valve replacement (TAVR), is a minimally invasive surgical procedure, which is performed to treat high-risk patients suffering from aortic stenosis. These high-risk patients refer to the patient population who cannot undergo surgical aortic valve replacement (SAVR) procedure. Older population (above 75 years of age) falls under the high-risk category, as the open-heart procedure is too risky for them. TAVR involves implantation of transcatheter aortic valves to regenerate the blood circulation ability of the aortic valve. The need of transcatheter aortic valve implantation is on the rise due to the increase in prevalence of aortic stenosis.
TAVI experiences market growth due to rise in geriatric population. Furthermore, advancements in the transcatheter aortic valves and increase in adoption rate of TAVI devices drive the market. However, stringent government regulations for approval of transcatheter aortic valves, which are class III medical devices and high cost associated with TAVI hamper the market growth. Conversely, use of TAVI systems for new indications, rise in healthcare expenditure in emerging economies, and increase in the interest of key players in the TAVI market are projected to provide several growth opportunities for the market throughout the forecast period.
The report segments the TAVI market based on procedure and region. According to procedure, it is classified into transfemoral implantation, transapical implantation, and transaortic implantation. Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, Switzerland, UK, and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of Asia-Pacific), and LAMEA (Brazil, Israel, South Africa, Saudi Arabia, and Rest of LAMEA).
KEY BENEFITS
- This report provides an extensive analysis of the current and emerging market trends, and dynamics in the global TAVI market.
- An in-depth analysis is conducted by constructing market estimations for the key segments between 2017 and 2025.
- This report entails the detailed quantitative analysis of the current trends and future estimations through 2017–2025, which assists to identify the prevailing opportunities.
- Comprehensive analysis of factors that drive and restrict the growth of the TAVI market is provided.
- An in-depth analysis of the current research and clinical developments within the TAVI market is provided.
- Key players are profiled, and their strategies are analyzed thoroughly, which interprets the competitive outlook of the market.
By Procedure
- Transfemoral Implantation
- Transapical Implantation
- Transaortic Implantation
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- Italy
- Switzerland
- UK
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Israel
- South Africa
- Saudi Arabia
- Rest of LAMEA
- Abbott Laboratories
- Boston Scientific Corporation (Symetis SA)
- Bracco S.p.A. (HLT, Inc.)
- Edwards Lifesciences Corporation
- JenaValve Technology, Inc.
- JC Medical, Inc.
- Medtronic plc
- Meril Life Sciences Pvt. Ltd.
- NVT AG
- Venus Medtech, Inc.
CHAPTER 1: INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. KEY PLAYERS
1.5. RESEARCH METHODOLOGY
1.5.1. Secondary research
1.5.2. Primary research
1.5.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE
CHAPTER 3: MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PORTERS FIVE FORCES ANALYSIS
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of new entrants
3.3.4. Intensity of rivalry
3.3.5. Threat of substitutes
3.4. MARKET SHARE ANALYSIS, 2017
3.5. GOVERNMENT REGULATIONS
3.5.1. U.S. FDA
3.5.2. Europe CE Mark
3.5.3. Ministry of Health, Labour and Welfare (MHLW)
3.6. CLINICAL TRIALS
3.7. MARKET DYNAMICS
3.7.1. Drivers
3.7.1.1. Rise in prevalence of aortic stenosis coupled with increase in geriatric population
3.7.1.2. Increase in adoption rate for transcatheter aortic valve implantation procedure
3.7.1.3. Increase in clinical evidence of safety and efficacy and new device approvals
3.7.1.4. Increase in number of TAVR Centers
3.7.2. Restraints
3.7.2.1. High cost of the device and unfavorable reimbursement policies
3.7.2.2. Stringent regulatory approval process
3.7.3. Opportunities
3.7.3.1. Use of TAVI systems for new indications
3.7.3.2. Rise in healthcare expenditure of developing countries
3.7.3.3. Increase in interest of local to global players in the TAVI market
3.7.4. Impact Analyses
CHAPTER 4: TRANSCATHETER AORTIC VALVE IMPLANTATION MARKET, BY PROCEDURE
4.1. OVERVIEW
4.1.1. Key market trends, growth factors, and opportunities
4.1.2. Market size and forecast
4.1.3. Market volume and forecast
4.2. TRANSFEMORAL (TF) IMPLANTATION
4.2.1. Market size and forecast
4.2.2. Market volume and forecast
4.3. TRANSAPICAL (TA) IMPLANTATION
4.3.1. Market size and forecast
4.3.2. Market volume and forecast
4.4. TRANSAORTIC IMPLANTATION
4.4.1. Market size and forecast
4.4.2. Market volume and forecast
CHAPTER 5: TRANSCATHETER AORTIC VALVE IMPLANTATION MARKET, BY REGION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.1.2. Market volume and forecast
5.2. NORTH AMERICA
5.2.1. Key market trends, growth factors, and opportunities
5.2.2. Market size and forecast, by country
5.2.3. Market volume and forecast, by country
5.2.3.1. U.S.
5.2.3.2. Canada
5.2.3.3. Mexico
5.2.4. Market size and forecast, by procedure
5.2.5. Market volume and forecast, by procedure
5.3. EUROPE
5.3.1. Key market trends, growth factors, and opportunities
5.3.2. Market size and forecast, by country
5.3.3. Market volume and forecast, by country
5.3.3.1. Germany
5.3.3.2. France
5.3.3.3. Italy
5.3.3.4. Switzerland
5.3.3.5. UK
5.3.3.6. Rest of Europe
5.3.4. Market size and forecast, by procedure
5.3.5. Market volume and forecast, by procedure
5.4. ASIA-PACIFIC
5.4.1. Key market trends, growth factors, and opportunities
5.4.2. Market size and forecast, by country
5.4.3. Market volume and forecast, by country
5.4.3.1. Japan
5.4.3.2. China
5.4.3.3. India
5.4.3.4. Rest of Asia-Pacific
5.4.4. Market size and forecast, by procedure
5.4.5. Market volume and forecast, by procedure
5.5. LAMEA
5.5.1. Key market trends, growth factors, and opportunities
5.5.2. Market size and forecast, by country
5.5.3. Market volume and forecast, by country
5.5.3.1. Brazil
5.5.3.2. South Africa
5.5.3.3. Israel
5.5.3.4. Saudi Arabia
5.5.3.5. Rest of LAMEA
5.5.4. Market size and forecast, by procedure
5.5.5. Market volume and forecast, by procedure
CHAPTER 6: COMPANY PROFILES
6.1. ABBOTT LABORATORIES (ST. JUDE MEDICAL, INC.)
6.1.1. Company overview
6.1.2. Company snapshot
6.1.3. Operating business segments
6.1.4. Product portfolio
6.1.5. Business performance
6.1.6. Key strategic moves and developments
6.2. BOSTON SCIENTIFIC CORPORATION (SYMETIS SA)
6.2.1. Company overview
6.2.2. Company snapshot
6.2.3. Operating business segments
6.2.4. Product portfolio
6.2.5. Business performance
6.2.6. Key strategic moves and developments
6.3. BRACCO S.P.A. (HLT, INC.)
6.3.1. Company overview
6.3.2. Company snapshot
6.3.3. Operating business segments
6.3.4. Product portfolio
6.3.5. Business performance
6.4. EDWARDS LIFESCIENCES CORPORATION
6.4.1. Company overview
6.4.2. Company snapshot
6.4.3. Operating business segments
6.4.4. Product portfolio
6.4.5. Business performance
6.4.6. Key strategic moves and developments
6.5. JENAVALVE TECHNOLOGY, INC.
6.5.1. Company overview
6.5.2. Company snapshot
6.5.3. Product portfolio
6.6. JC MEDICAL, INC.
6.6.1. Company overview
6.6.2. Company snapshot
6.6.3. Product portfolio
6.6.4. Key strategic moves and developments
6.7. MEDTRONIC PLC.
6.7.1. Company overview
6.7.2. Company snapshot
6.7.3. Operating business segments
6.7.4. Product portfolio
6.7.5. Business performance
6.7.6. Key strategic moves and developments
6.8. MERIL LIFE SCIENCES PVT. LTD.
6.8.1. Company overview
6.8.2. Company snapshot
6.8.3. Operating business segments
6.8.4. Product portfolio
6.9. NVT AG
6.9.1. Company overview
6.9.2. Company snapshot
6.9.3. Product portfolio
6.10. VENUS MEDTECH, INC.
6.10.1. Company overview
6.10.2. Company snapshot
6.10.3. Product portfolio
6.10.4. Key strategic moves and developments
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. KEY PLAYERS
1.5. RESEARCH METHODOLOGY
1.5.1. Secondary research
1.5.2. Primary research
1.5.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE
CHAPTER 3: MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PORTERS FIVE FORCES ANALYSIS
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of new entrants
3.3.4. Intensity of rivalry
3.3.5. Threat of substitutes
3.4. MARKET SHARE ANALYSIS, 2017
3.5. GOVERNMENT REGULATIONS
3.5.1. U.S. FDA
3.5.2. Europe CE Mark
3.5.3. Ministry of Health, Labour and Welfare (MHLW)
3.6. CLINICAL TRIALS
3.7. MARKET DYNAMICS
3.7.1. Drivers
3.7.1.1. Rise in prevalence of aortic stenosis coupled with increase in geriatric population
3.7.1.2. Increase in adoption rate for transcatheter aortic valve implantation procedure
3.7.1.3. Increase in clinical evidence of safety and efficacy and new device approvals
3.7.1.4. Increase in number of TAVR Centers
3.7.2. Restraints
3.7.2.1. High cost of the device and unfavorable reimbursement policies
3.7.2.2. Stringent regulatory approval process
3.7.3. Opportunities
3.7.3.1. Use of TAVI systems for new indications
3.7.3.2. Rise in healthcare expenditure of developing countries
3.7.3.3. Increase in interest of local to global players in the TAVI market
3.7.4. Impact Analyses
CHAPTER 4: TRANSCATHETER AORTIC VALVE IMPLANTATION MARKET, BY PROCEDURE
4.1. OVERVIEW
4.1.1. Key market trends, growth factors, and opportunities
4.1.2. Market size and forecast
4.1.3. Market volume and forecast
4.2. TRANSFEMORAL (TF) IMPLANTATION
4.2.1. Market size and forecast
4.2.2. Market volume and forecast
4.3. TRANSAPICAL (TA) IMPLANTATION
4.3.1. Market size and forecast
4.3.2. Market volume and forecast
4.4. TRANSAORTIC IMPLANTATION
4.4.1. Market size and forecast
4.4.2. Market volume and forecast
CHAPTER 5: TRANSCATHETER AORTIC VALVE IMPLANTATION MARKET, BY REGION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.1.2. Market volume and forecast
5.2. NORTH AMERICA
5.2.1. Key market trends, growth factors, and opportunities
5.2.2. Market size and forecast, by country
5.2.3. Market volume and forecast, by country
5.2.3.1. U.S.
5.2.3.2. Canada
5.2.3.3. Mexico
5.2.4. Market size and forecast, by procedure
5.2.5. Market volume and forecast, by procedure
5.3. EUROPE
5.3.1. Key market trends, growth factors, and opportunities
5.3.2. Market size and forecast, by country
5.3.3. Market volume and forecast, by country
5.3.3.1. Germany
5.3.3.2. France
5.3.3.3. Italy
5.3.3.4. Switzerland
5.3.3.5. UK
5.3.3.6. Rest of Europe
5.3.4. Market size and forecast, by procedure
5.3.5. Market volume and forecast, by procedure
5.4. ASIA-PACIFIC
5.4.1. Key market trends, growth factors, and opportunities
5.4.2. Market size and forecast, by country
5.4.3. Market volume and forecast, by country
5.4.3.1. Japan
5.4.3.2. China
5.4.3.3. India
5.4.3.4. Rest of Asia-Pacific
5.4.4. Market size and forecast, by procedure
5.4.5. Market volume and forecast, by procedure
5.5. LAMEA
5.5.1. Key market trends, growth factors, and opportunities
5.5.2. Market size and forecast, by country
5.5.3. Market volume and forecast, by country
5.5.3.1. Brazil
5.5.3.2. South Africa
5.5.3.3. Israel
5.5.3.4. Saudi Arabia
5.5.3.5. Rest of LAMEA
5.5.4. Market size and forecast, by procedure
5.5.5. Market volume and forecast, by procedure
CHAPTER 6: COMPANY PROFILES
6.1. ABBOTT LABORATORIES (ST. JUDE MEDICAL, INC.)
6.1.1. Company overview
6.1.2. Company snapshot
6.1.3. Operating business segments
6.1.4. Product portfolio
6.1.5. Business performance
6.1.6. Key strategic moves and developments
6.2. BOSTON SCIENTIFIC CORPORATION (SYMETIS SA)
6.2.1. Company overview
6.2.2. Company snapshot
6.2.3. Operating business segments
6.2.4. Product portfolio
6.2.5. Business performance
6.2.6. Key strategic moves and developments
6.3. BRACCO S.P.A. (HLT, INC.)
6.3.1. Company overview
6.3.2. Company snapshot
6.3.3. Operating business segments
6.3.4. Product portfolio
6.3.5. Business performance
6.4. EDWARDS LIFESCIENCES CORPORATION
6.4.1. Company overview
6.4.2. Company snapshot
6.4.3. Operating business segments
6.4.4. Product portfolio
6.4.5. Business performance
6.4.6. Key strategic moves and developments
6.5. JENAVALVE TECHNOLOGY, INC.
6.5.1. Company overview
6.5.2. Company snapshot
6.5.3. Product portfolio
6.6. JC MEDICAL, INC.
6.6.1. Company overview
6.6.2. Company snapshot
6.6.3. Product portfolio
6.6.4. Key strategic moves and developments
6.7. MEDTRONIC PLC.
6.7.1. Company overview
6.7.2. Company snapshot
6.7.3. Operating business segments
6.7.4. Product portfolio
6.7.5. Business performance
6.7.6. Key strategic moves and developments
6.8. MERIL LIFE SCIENCES PVT. LTD.
6.8.1. Company overview
6.8.2. Company snapshot
6.8.3. Operating business segments
6.8.4. Product portfolio
6.9. NVT AG
6.9.1. Company overview
6.9.2. Company snapshot
6.9.3. Product portfolio
6.10. VENUS MEDTECH, INC.
6.10.1. Company overview
6.10.2. Company snapshot
6.10.3. Product portfolio
6.10.4. Key strategic moves and developments
LIST OF TABLES
TABLE 01. MAJOR TAVI APPROVED DEVICES
TABLE 02. GLOBAL TAVI MARKET REVENUE, BY PROCEDURE, 2017-2025 ($MILLION)
TABLE 03. GLOBAL TAVI MARKET VOLUME, BY PROCEDURE, 2017-2025 (UNITS)
TABLE 04. TRANSFEMORAL IMPLANTATION MARKET REVENUE, BY REGION, 2017-2025 ($MILLION)
TABLE 05. TRANSFEMORAL IMPLANTATION MARKET VOLUME, BY REGION, 2017-2025 (UNITS)
TABLE 06. TRANSAPICAL IMPLANTATION MARKET REVENUE, BY REGION, 2017-2025 ($MILLION)
TABLE 07. TRANSAPICAL IMPLANTATION MARKET VOLUME, BY REGION, 2017-2025 (UNITS)
TABLE 08. TRANSAORTIC IMPLANTATION MARKET REVENUE, BY REGION, 2017-2025 ($MILLION)
TABLE 09. TRANSAORTIC IMPLANTATION MARKET VOLUME, BY REGION, 2017-2025 (UNITS)
TABLE 10. TAVI MARKET REVENUE, BY REGION, 2017-2025 ($MILLION)
TABLE 11. TAVI MARKET VOLUME, BY REGION, 2017-2025 (UNITS)
TABLE 12. NORTH AMERICA TAVI MARKET REVENUE, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 13. NORTH AMERICA TAVI MARKET VOLUME, BY COUNTRY, 2017-2025 (UNITS)
TABLE 14. NORTH AMERICA TAVI MARKET REVENUE, BY PROCEDURE, 2017-2025 ($MILLION)
TABLE 15. NORTH AMERICA TAVI MARKET VOLUME, BY PROCEDURE, 2017-2025 (UNITS)
TABLE 16. EUROPE TAVI MARKET REVENUE, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 17. EUROPE TAVI MARKET VOLUME, BY COUNTRY, 2017-2025 (UNITS)
TABLE 18. EUROPE TAVI MARKET REVENUE, BY PROCEDURE, 2017-2025 ($MILLION)
TABLE 19. EUROPE TAVI MARKET VOLUME, BY PROCEDURE, 2017-2025 (UNITS)
TABLE 20. ASIA-PACIFIC TAVI MARKET REVENUE, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 21. ASIA-PACIFIC TAVI MARKET VOLUME, BY COUNTRY, 2017-2025 (UNITS)
TABLE 22. ASIA-PACIFIC TAVI MARKET REVENUE, BY PROCEDURE, 2017-2025 ($MILLION)
TABLE 23. ASIA-PACIFIC TAVI MARKET VOLUME, BY PROCEDURE, 2017-2025 (UNITS)
TABLE 24. LAMEA TAVI MARKET REVENUE, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 25. LAMEA TAVI MARKET VOLUME, BY COUNTRY, 2017-2025 (UNITS)
TABLE 26. LAMEA TAVI MARKET REVENUE, BY PROCEDURE, 2017-2025 ($MILLION)
TABLE 27. LAMEA TAVI MARKET VOLUME, BY PROCEDURE, 2017-2025 (UNITS)
TABLE 28. ABBOTT: COMPANY SNAPSHOT
TABLE 29. ABBOTT: OPERATING SEGMENTS
TABLE 30. ABBOTT: PRODUCT PORTFOLIO
TABLE 31. BOSTON SCIENTIFIC: COMPANY SNAPSHOT
TABLE 32. BOSTON SCIENTIFIC: OPERATING SEGMENTS
TABLE 33. BOSTON SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 34. BRACCO: COMPANY SNAPSHOT
TABLE 35. BRACCO: OPERATING SEGMENTS
TABLE 36. BRACCO: PRODUCT PORTFOLIO
TABLE 37. EDWARDS LIFESCIENCES: COMPANY SNAPSHOT
TABLE 38. EDWARDS LIFESCIENCES: PRODUCT PORTFOLIO
TABLE 39. JENAVALVE: COMPANY SNAPSHOT
TABLE 40. JENAVALVE: PRODUCT PORTFOLIO
TABLE 41. JC MEDICAL: COMPANY SNAPSHOT
TABLE 42. JC MEDICAL: PRODUCT PORTFOLIO
TABLE 43. MEDTRONIC: COMPANY SNAPSHOT
TABLE 44. MEDTRONIC: OPERATING SEGMENTS
TABLE 45. MEDTRONIC: PRODUCT PORTFOLIO
TABLE 46. MERIL: COMPANY SNAPSHOT
TABLE 47. MERIL: PRODUCT SEGMENTS
TABLE 48. MERIL: PRODUCT PORTFOLIO
TABLE 49. NVT: COMPANY SNAPSHOT
TABLE 50. NVT: PRODUCT PORTFOLIO
TABLE 51. VENUS MEDTECH: COMPANY SNAPSHOT
TABLE 52. VENUS MEDTECH: PRODUCT PORTFOLIO
TABLE 01. MAJOR TAVI APPROVED DEVICES
TABLE 02. GLOBAL TAVI MARKET REVENUE, BY PROCEDURE, 2017-2025 ($MILLION)
TABLE 03. GLOBAL TAVI MARKET VOLUME, BY PROCEDURE, 2017-2025 (UNITS)
TABLE 04. TRANSFEMORAL IMPLANTATION MARKET REVENUE, BY REGION, 2017-2025 ($MILLION)
TABLE 05. TRANSFEMORAL IMPLANTATION MARKET VOLUME, BY REGION, 2017-2025 (UNITS)
TABLE 06. TRANSAPICAL IMPLANTATION MARKET REVENUE, BY REGION, 2017-2025 ($MILLION)
TABLE 07. TRANSAPICAL IMPLANTATION MARKET VOLUME, BY REGION, 2017-2025 (UNITS)
TABLE 08. TRANSAORTIC IMPLANTATION MARKET REVENUE, BY REGION, 2017-2025 ($MILLION)
TABLE 09. TRANSAORTIC IMPLANTATION MARKET VOLUME, BY REGION, 2017-2025 (UNITS)
TABLE 10. TAVI MARKET REVENUE, BY REGION, 2017-2025 ($MILLION)
TABLE 11. TAVI MARKET VOLUME, BY REGION, 2017-2025 (UNITS)
TABLE 12. NORTH AMERICA TAVI MARKET REVENUE, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 13. NORTH AMERICA TAVI MARKET VOLUME, BY COUNTRY, 2017-2025 (UNITS)
TABLE 14. NORTH AMERICA TAVI MARKET REVENUE, BY PROCEDURE, 2017-2025 ($MILLION)
TABLE 15. NORTH AMERICA TAVI MARKET VOLUME, BY PROCEDURE, 2017-2025 (UNITS)
TABLE 16. EUROPE TAVI MARKET REVENUE, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 17. EUROPE TAVI MARKET VOLUME, BY COUNTRY, 2017-2025 (UNITS)
TABLE 18. EUROPE TAVI MARKET REVENUE, BY PROCEDURE, 2017-2025 ($MILLION)
TABLE 19. EUROPE TAVI MARKET VOLUME, BY PROCEDURE, 2017-2025 (UNITS)
TABLE 20. ASIA-PACIFIC TAVI MARKET REVENUE, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 21. ASIA-PACIFIC TAVI MARKET VOLUME, BY COUNTRY, 2017-2025 (UNITS)
TABLE 22. ASIA-PACIFIC TAVI MARKET REVENUE, BY PROCEDURE, 2017-2025 ($MILLION)
TABLE 23. ASIA-PACIFIC TAVI MARKET VOLUME, BY PROCEDURE, 2017-2025 (UNITS)
TABLE 24. LAMEA TAVI MARKET REVENUE, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 25. LAMEA TAVI MARKET VOLUME, BY COUNTRY, 2017-2025 (UNITS)
TABLE 26. LAMEA TAVI MARKET REVENUE, BY PROCEDURE, 2017-2025 ($MILLION)
TABLE 27. LAMEA TAVI MARKET VOLUME, BY PROCEDURE, 2017-2025 (UNITS)
TABLE 28. ABBOTT: COMPANY SNAPSHOT
TABLE 29. ABBOTT: OPERATING SEGMENTS
TABLE 30. ABBOTT: PRODUCT PORTFOLIO
TABLE 31. BOSTON SCIENTIFIC: COMPANY SNAPSHOT
TABLE 32. BOSTON SCIENTIFIC: OPERATING SEGMENTS
TABLE 33. BOSTON SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 34. BRACCO: COMPANY SNAPSHOT
TABLE 35. BRACCO: OPERATING SEGMENTS
TABLE 36. BRACCO: PRODUCT PORTFOLIO
TABLE 37. EDWARDS LIFESCIENCES: COMPANY SNAPSHOT
TABLE 38. EDWARDS LIFESCIENCES: PRODUCT PORTFOLIO
TABLE 39. JENAVALVE: COMPANY SNAPSHOT
TABLE 40. JENAVALVE: PRODUCT PORTFOLIO
TABLE 41. JC MEDICAL: COMPANY SNAPSHOT
TABLE 42. JC MEDICAL: PRODUCT PORTFOLIO
TABLE 43. MEDTRONIC: COMPANY SNAPSHOT
TABLE 44. MEDTRONIC: OPERATING SEGMENTS
TABLE 45. MEDTRONIC: PRODUCT PORTFOLIO
TABLE 46. MERIL: COMPANY SNAPSHOT
TABLE 47. MERIL: PRODUCT SEGMENTS
TABLE 48. MERIL: PRODUCT PORTFOLIO
TABLE 49. NVT: COMPANY SNAPSHOT
TABLE 50. NVT: PRODUCT PORTFOLIO
TABLE 51. VENUS MEDTECH: COMPANY SNAPSHOT
TABLE 52. VENUS MEDTECH: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. TAVI MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2015-2018
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2018 (%)
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2015-2018
FIGURE 06. MARKET SHARE ANALYSIS, 2017
FIGURE 07. CLINICAL TRIALS IN TAVR MARKET, BY REGION, 2015-2018
FIGURE 08. IMPACT ANALYSES, TAVI MARKET
FIGURE 09. U.S. TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 10. CANADA TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 11. MEXICO TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 12. GERMANY TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 13. FRANCE TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 14. ITALY TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 15. SWITZERLAND TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 16. UK TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 17. REST OF EUROPE TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 18. JAPAN TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 19. CHINA TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 20. INDIA TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 21. REST OF ASIA-PACIFIC TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 22. BRAZIL TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 23. SOUTH AFRICA TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 24. ISRAEL TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 25. SAUDI ARABIA TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 26. REST OF LAMEA TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 27. ABBOTT: NET SALES, 2015-2017 ($MILLION)
FIGURE 28. ABBOTT: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 29. ABBOTT: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 30. BOSTON SCIENTIFIC: NET SALES, 2015-2017 ($MILLION)
FIGURE 31. BOSTON SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 32. BOSTON SCIENTIFIC: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 33. BRACCO: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 34. BRACCO: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 35. EDWARDS LIFESCIENCES: NET SALES, 2015-2017 ($MILLION)
FIGURE 36. EDWARDS LIFESCIENCES: REVENUE SHARE BY PRODUCT, 2017 (%)
FIGURE 37. EDWARDS LIFESCIENCES: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 38. MEDTRONIC: NET SALES, 2015-2017 ($MILLION)
FIGURE 39. MEDTRONIC: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 40. MEDTRONIC: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 01. TAVI MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2015-2018
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2018 (%)
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2015-2018
FIGURE 06. MARKET SHARE ANALYSIS, 2017
FIGURE 07. CLINICAL TRIALS IN TAVR MARKET, BY REGION, 2015-2018
FIGURE 08. IMPACT ANALYSES, TAVI MARKET
FIGURE 09. U.S. TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 10. CANADA TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 11. MEXICO TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 12. GERMANY TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 13. FRANCE TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 14. ITALY TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 15. SWITZERLAND TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 16. UK TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 17. REST OF EUROPE TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 18. JAPAN TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 19. CHINA TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 20. INDIA TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 21. REST OF ASIA-PACIFIC TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 22. BRAZIL TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 23. SOUTH AFRICA TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 24. ISRAEL TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 25. SAUDI ARABIA TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 26. REST OF LAMEA TAVI MARKET (VALUE AND VOLUME), 2017-2025
FIGURE 27. ABBOTT: NET SALES, 2015-2017 ($MILLION)
FIGURE 28. ABBOTT: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 29. ABBOTT: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 30. BOSTON SCIENTIFIC: NET SALES, 2015-2017 ($MILLION)
FIGURE 31. BOSTON SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 32. BOSTON SCIENTIFIC: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 33. BRACCO: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 34. BRACCO: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 35. EDWARDS LIFESCIENCES: NET SALES, 2015-2017 ($MILLION)
FIGURE 36. EDWARDS LIFESCIENCES: REVENUE SHARE BY PRODUCT, 2017 (%)
FIGURE 37. EDWARDS LIFESCIENCES: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 38. MEDTRONIC: NET SALES, 2015-2017 ($MILLION)
FIGURE 39. MEDTRONIC: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 40. MEDTRONIC: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
